Jan Patton
Director of Investor Relations and Communication
Replay available
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call
Oncolytics Biotech Inc. (NASDAQ: ONCY) Q4 2024 earnings conference call, held 2025-03-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Michael Freeman
Analyst, Raymond James
Unidentified Executive
Executive (not explicitly identified in the transcript)
Christophe Deglois
Vice President of Business Development
Wayne Pisano
Chairman of the Board & Interim CEO
Dr. Tom Heinemann
Chief Medical Officer
Kirk Look
Chief Financial Officer
Unidentified Participant
Participant (unidentified in the transcript)
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Oncolytics Biotech Inc..
Replay transcript excerpt
WEBVTT 00:00:00.942 -- 00:00:06.651 Good morning and welcome to Oncolytics Biotech's fourth quarter and full year 2024 00:00:06.651 -- 00:00:10.798 conference call. All participants are in a listen-only mode. 00:00:10.798 -- 00:00:14.083 There will be a question and answer session at the end of the call. 00:00:14.083 -- 00:00:18.630 Please be advised that this call is being recorded at the company's request. 00:00:18.630 -- 00:00:22.636 I would now like to turn the call over to Jan Patton, Director of Investor Relations 00:00:22.636 -- 00:00:25.601 and Communication. Please go ahead. 00:00:25.601 -- 00:00:30.167 Thank you, Operator. Good morning, everyone, and welcome to Oncolitic's fourth quarter 00:00:30.167 -- 00:00:35.173 and full year 2024 earnings call. As a reminder, various remarks made during this call 00:00:35.173 -- 00:00:38.698 contain certain forward-looking statements relating to the company's business prospects 00:00:38.698 -- 00:00:42.443 and the development and commercialization of Pella ReRep, including statements regarding 00:00:42.443 -- 00:00:46.868 the company's mission, strategy, and milestones, the company's belief as to the potential 00:00:46.868 -- 00:00:51.174 and mechanism of action of Pella ReRep as a cancer therapeutic, our search for a new 00:00:51.174 -- 00:00:55.802 permanent CEO, our potential registrational opportunities for Pella ReRap and our plans 00:00:55.802 -- 00:01:00.768 and strategies related thereto, the potential market for Pella ReRap and breast cancer, 00:01:00.768 -- 00:01:05.194 our plans to continue enrollment in Goblet Cohort 5, our ongoing business development 00:01:05.194 -- 00:01:08.978 initiatives, and other statements related to anticipated developments in the company's 00:01:08.978 -- 00:01:13.023 business. Th...